ArticleScience advances2020
Efficient high-throughput SARS-CoV-2 testing to detect asymptomatic carriers.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2020Pooled it
- Combinatorial group testing for efficient scaling across biological applications.Nature communications · 2026Article
- Review
- Enhancing RT-PCR Throughput and Sensitivity through Large-Scale Sample Pooling Using a Nano-Hybrid Membrane.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A proactive/reactive mass screening approach with uncertain symptomatic cases.PLoS computational biology · 2024Article
- High capacity clinical SARS-CoV-2 molecular testing using combinatorial pooling.Communications medicine · 2024Article
- Comparative Bioinformatic Analysis Reveals Conserved Regions in SARS-CoV-2 Genome for RAPID Pandemic Response.International journal of molecular sciences · 2024Article
- Clinical performance of AI-integrated risk assessment pooling reveals cost savings even at high prevalence of COVID-19.Scientific reports · 2024Article
- Bayesian group testing with dilution effects.Biostatistics (Oxford, England) · 2023Article
- Magnetic Janus origami robot for cross-scale droplet omni-manipulation.Nature communications · 2023Article
- MultiplexMS: A Mass Spectrometry-Based Multiplexing Strategy for Ultra-High-Throughput Analysis of Complex Mixtures.Analytical chemistry · 2023Article
- Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives.Chemical science · 2023Review
- CoVSense: Ultrasensitive Nucleocapsid Antigen Immunosensor for Rapid Clinical Detection of Wildtype and Variant SARS-CoV-2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Effective matrix designs for COVID-19 group testing.BMC bioinformatics · 2023Review
- Operational analysis for COVID-19 testing: Determining the risk from asymptomatic infections.PloS one · 2023Article
- Group Testing with Blocks of Positives and Inhibitors.Entropy (Basel, Switzerland) · 2022Article
- Use of compressed sensing to expedite high-throughput diagnostic testing for COVID-19 and beyond.PLoS computational biology · 2022Article
- Article
- Mitigation of SARS-CoV-2 transmission at a large public university.Nature communications · 2022Article
- Effective bubble-based testing for SARS-CoV-2 using swab-pooling.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent reports suggest that 10 to 30% of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infected patients are asymptomatic and that viral shedding may occur before symptom onset. Therefore, there is an urgent need to increase diagnostic testing capabilities to prevent disease spread. We developed P-BEST, a method for Pooling-Based Efficient SARS-CoV-2 Testing, which identifies all positive subjects within a set of samples using a single round of testing. Each sample is assigned into multiple pools using a combinatorial pooling strategy based on compressed sensing. We pooled sets of 384 samples into 48 pools, providing both an eightfold increase in testing efficiency and an eightfold reduction in test costs, while identifying up to five positive carriers. We then used P-BEST to screen 1115 health care workers using 144 tests. P- BEST provides an efficient and easy-to-implement solution for increasing testing capacity that can be easily integrated into diagnostic laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.